1 option
Biomarkers in oncology : overview / Joe Duffy.
- Format:
- Video
- Author/Creator:
- Duffy, Joe, author.
- Language:
- English
- Subjects (All):
- Biochemical markers.
- Physical Description:
- 1 streaming video file (27 min.) : sound, color
- Other Title:
- Biomarkers in oncology
- Place of Publication:
- London, England : Henry Stewart Talks Ltd, 2016.
- System Details:
- video file
- Contents:
- Introduction
- Tumor (bio)marker: definition
- Potential uses of tumor markers
- Cancer predisposing genes
- Genetic testing for cancer susceptibility: ASCO
- Use of tumor markers in screening
- Recommended cancer screening tests
- Markers under evaluation or previously evaluated
- PSA as a screening test for PCa
- PSA screening is controversial
- PSA as a screening test for PCa: way forward
- Ongoing trials evaluating PSA screening for Pca
- PSA screening: ACS guidelines
- PSA screening: USPSTF guidelines
- PSA screening: EGTM recommendations
- Use of tumor markers in aiding diagnosis
- When can merkers aid cancer diagnosis
- Use of markers in aiding the diagnosis of CUP
- Use of markers for differential diagnosis
- Diagnosis using CA 125: EGTM guidelines
- AFP as a diagnostic aid in HCC
- Use of tumor markers in assessing prognosis
- Markers can be used to determine prognosis
- Prognostic markers: clinical use
- Tissue markers and prognosis in breast cancer
- ER as a prognostic marker in breast cancer
- HER-2 as a prognostic marker in breast cancer
- uPA/PAI-1 prognostic marker in breast cancer
- uPA and PAI-1: ASCO recommendation (1)
- Oncotype DX test
- Oncotype DX test: ASCO recommendation
- MammaPrint
- Serum markers for determining prognosis
- Use of markers in predicting response to therpay
- Why do we need therapy predictive markers
- Response rates in patients with advanced cancers
- Predictive markers
- ER as a therapy predictive marker in breast cancer
- HER-2 as a predictive marker in breast cancer
- Herceptin in treatment of breast cancer
- HER-2 for predicting response to herceptin
- Emerging therapy predictive markers
- Use of markers in predicting therapy toxicity
- Markers for predicting anti-cancer agents toxicity
- Use of tumor markers in postoperative surveillance
- Markers in postoperative surveillance: rationale
- Tumor markers used in postoperative surveillance
- Critical question
- Intensive vs. control follow-up in CRC
- Follow-up of CRC patients: role of CEA
- Use of CEA in follow-up: EGTM recommendations
- Use of CEA in follow-up: ASCO recommendations
- Use of tumor markers in monitoring therapy
- Markers used in monitoring advanced disease
- Markers in surveillance and monitoring: caveats
- Acknowlegement.
- Notes:
- Description based on publisher supplied metadata and other sources.
- Retrieved April 9, 2024, from https://hstalks.com/bs/1118/.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.